- $808.98m
- $791.39m
- $169.33m
- 90
- 25
- 80
- 71
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.39 | ||
| Price to Tang. Book | 3.55 | ||
| Price to Free Cashflow | 29.23 | ||
| Price to Sales | 4.45 | ||
| EV to EBITDA | 26.21 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.93% | ||
| Return on Equity | 5.23% | ||
| Operating Margin | 7.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 155.07 | 147.59 | 165.01 | 183.51 | 169.33 | n/a | n/a | 2.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +6.98 | -11.56 | +4.23 | +7.56 | -43.64 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Directors
- Emile Battat CHM (83)
- David Battat CEO (51)
- Jeffery Strickland CFO (62)
- Ronald Spaulding LED (57)
- Preston Athey IND (71)
- Hugh Morgan IND (92)
- Maria Sainz IND (55)
- John Stupp IND (71)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 30th, 1996
- Public Since
- March 18th, 1980
- No. of Shareholders
- 15,180
- No. of Employees
- 712
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 1,759,954
- Address
- One Allentown Parkway, ALLEN, 75002
- Web
- https://atrioncorp.com/
- Phone
- +1 9723909800
- Auditors
- Grant Thornton LLP
Upcoming Events for ATRI
Similar to ATRI
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Atrion share price?
As of Today at 23:21 UTC, shares in Atrion are trading at $459.66. This share price information is delayed by 15 minutes.
How has the Atrion share price performed this year?
Shares in Atrion last closed at $459.66 and the price had moved by -5.65% over the past 365 days. In terms of relative price strength the Atrion share price has underperformed the S&P500 Index by -25.98% over the past year.
What are the analyst and broker recommendations for Atrion?
The overall consensus recommendation for Atrion is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Atrion dividend yield?
The Atrion dividend yield is 1.91% based on the trailing twelve month period.
Does Atrion pay a dividend?
Last year, Atrion paid a total dividend of $8.80, and it currently has a trailing dividend yield of 1.91%. We do not have any data on when Atrion is to next pay dividends.
When does Atrion next pay dividends?
We do not have data on when Atrion is to next pay dividends. The historic dividend yield on Atrion shares is currently 1.91%.
How do I buy Atrion shares?
To buy shares in Atrion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Atrion?
As of the previous close price of $459.66, shares in Atrion had a market capitalisation of $808.98m.
Where are Atrion shares listed?
Here are the trading details for Atrion:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ATRI
What kind of share is Atrion?
Based on an overall assessment of its quality, value and momentum Atrion is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Atrion share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Atrion share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atrion. Over the past six months, its share price has outperformed the S&P500 Index by +14.9%.
As of the last closing price of $459.66, shares in Atrion were trading +15.06% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Atrion PE Ratio?
The Atrion PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $459.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Atrion?
Atrion's management team is headed by:
- Emile Battat - CHM
- David Battat - CEO
- Jeffery Strickland - CFO
- Ronald Spaulding - LED
- Preston Athey - IND
- Hugh Morgan - IND
- Maria Sainz - IND
- John Stupp - IND